JP2016535038A - 抗菌剤を含む医薬品組成物 - Google Patents

抗菌剤を含む医薬品組成物 Download PDF

Info

Publication number
JP2016535038A
JP2016535038A JP2016526935A JP2016526935A JP2016535038A JP 2016535038 A JP2016535038 A JP 2016535038A JP 2016526935 A JP2016526935 A JP 2016526935A JP 2016526935 A JP2016526935 A JP 2016526935A JP 2016535038 A JP2016535038 A JP 2016535038A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable derivative
formula
sulbactam
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016526935A
Other languages
English (en)
Japanese (ja)
Inventor
サチン バグワット
サチン バグワット
マヘシュ ヴィタルバイ パテル
マヘシュ ヴィタルバイ パテル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of JP2016535038A publication Critical patent/JP2016535038A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016526935A 2013-10-30 2014-10-22 抗菌剤を含む医薬品組成物 Pending JP2016535038A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3422/MUM/2013 2013-10-30
PCT/IB2014/065523 WO2015063653A1 (en) 2013-10-30 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3422MU2013 IN2013MU03422A (enExample) 2013-10-30 2014-10-22

Publications (1)

Publication Number Publication Date
JP2016535038A true JP2016535038A (ja) 2016-11-10

Family

ID=52003013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526935A Pending JP2016535038A (ja) 2013-10-30 2014-10-22 抗菌剤を含む医薬品組成物

Country Status (10)

Country Link
US (1) US20160287571A1 (enExample)
EP (1) EP3062793A1 (enExample)
JP (1) JP2016535038A (enExample)
CN (1) CN106163519A (enExample)
AU (1) AU2014343327A1 (enExample)
CA (1) CA2928368A1 (enExample)
IN (1) IN2013MU03422A (enExample)
MX (1) MX2016005539A (enExample)
RU (1) RU2016115375A (enExample)
WO (1) WO2015063653A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016151543A1 (en) * 2015-03-25 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
US11180501B2 (en) 2017-12-01 2021-11-23 Qilu Pharmaceutical Co., Ltd. Crystal form of β-lactamase inhibitor and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030733A1 (en) * 2011-08-27 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013030733A1 (en) * 2011-08-27 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections

Also Published As

Publication number Publication date
CA2928368A1 (en) 2015-05-07
EP3062793A1 (en) 2016-09-07
CN106163519A (zh) 2016-11-23
MX2016005539A (es) 2016-10-03
RU2016115375A3 (enExample) 2018-07-18
RU2016115375A (ru) 2017-12-01
WO2015063653A1 (en) 2015-05-07
AU2014343327A1 (en) 2016-05-12
IN2013MU03422A (enExample) 2015-07-17
US20160287571A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
CN105792827B (zh) 抗菌组合物
JP6886996B2 (ja) 抗菌剤を含む医薬組成物
US9789097B2 (en) Pharmaceutical compositions comprising antibacterial agents
JP2017506240A (ja) 抗菌剤を含む医薬組成物
JP2017507162A (ja) 抗菌薬を含む医薬組成物
CN106163519A (zh) 包含抗菌剂的药物组合物
JP2017511359A (ja) 抗菌薬を含む医薬組成物
AU2014338612A1 (en) Pharmaceutical compositions comprising antibacterial agents
JP2017508769A (ja) セフェピムまたはスルバクタムを含む医薬組成物
WO2018193368A1 (en) Antibacterial compositions
KR20160072262A (ko) 항균제를 포함하는 제약학적 조성물
KR20160072253A (ko) 항균제를 포함하는 제약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160628

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170323

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181210